> We're seeing some signs of this, along with other changes in drug models: injectable hypertension treatment is in test. Imagine the impact on the cost basis of a pill-per-day model!
Tablets are generally dirt cheap to produce. Sterile injectables adds a lot of variables and requirements, both in production and sometimes also in distribution (cold chain?) and administration (directly and sometimes requiring reconstitution).
Maybe if you have an API that’s expensive to produce and has poor bioavailability an injectable might be cheaper.
A long acting injectable antihypertensive will have a place for some, but creates other issues: can’t stop it quickly and hypertension often requires multiple agents to treat.
in the United States, at least, (and until very, very recently, I believe), PrEP is required to be covered under healthcare; and, services like good rx make Truvada specifically very accessible in price, even free.
In the United States, please look into these services and what your insurance provider does cover because, at least for now, it should be *very* affordable. (between free w/insurance to $30/mo with GoodRX).
I do think that price is higher than I saw the last time I looked it up, but I don't have that search on hand to confirm.
Tablets are generally dirt cheap to produce. Sterile injectables adds a lot of variables and requirements, both in production and sometimes also in distribution (cold chain?) and administration (directly and sometimes requiring reconstitution).
Maybe if you have an API that’s expensive to produce and has poor bioavailability an injectable might be cheaper.
A long acting injectable antihypertensive will have a place for some, but creates other issues: can’t stop it quickly and hypertension often requires multiple agents to treat.
I wish poly-pills took off :(